Envoy Medical Meets $35M Nasdaq MVLS Requirement After Strategic Financing
Envoy Medical regained compliance with Nasdaq Listing Rule 5550(b)(2) by meeting the $35 million market value of listed securities requirement through strategic financing and balance sheet strengthening. The company implemented these initiatives after receiving a non-compliance notice in February 2025 and expects to sustain compliance on the Nasdaq Capital Market.
1. Nasdaq Listing Compliance Restored
In February 2026, Nasdaq confirmed that Envoy Medical evidenced compliance with Listing Rule 5550(b)(2) by satisfying the minimum $35 million market value of listed securities requirement through permitted alternatives under Rule 5550(b). This follows a notice of non-compliance issued on February 25, 2025, for falling below the MVLS threshold.
2. Strategic Financing and Balance Sheet Strength
After the non-compliance notice, Envoy Medical executed strategic financing initiatives—including private placements and equity offerings—to bolster its cash position and strengthen its balance sheet. These measures directly increased its market value of listed securities above the $35 million requirement.
3. Ongoing Compliance Plan
Envoy Medical has outlined an executable plan to maintain its Nasdaq compliance, focusing on financial discipline, potential incremental financing, and operational milestones. The company anticipates remaining listed on the Nasdaq Capital Market and continuing to trade under its existing symbol.